WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals, Inc. (INO) said its phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose. The company expects interim immune responses and safety results from the clinical trial in late June.
INO-4800 is the company's DNA vaccine candidate created to protect against the novel coronavirus SARS-CoV-2, which causes COVID-19. INO-4800 was rapidly designed using INOVIO's DNA medicine platform after the publication of the genetic sequence of the coronavirus that causes COVID-19.
Copyright RTT News/dpa-AFX
© 2020 AFX News
